183 related articles for article (PubMed ID: 28423708)
21. Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.
Lodhia KA; Gao S; Aleksic T; Esashi F; Macaulay VM
Int J Cancer; 2015 Jun; 136(12):2961-6. PubMed ID: 25388513
[TBL] [Abstract][Full Text] [Related]
22. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
23. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
24. DNA repair: Decision at the break point.
Boulton SJ
Nature; 2010 May; 465(7296):301-2. PubMed ID: 20485424
[No Abstract] [Full Text] [Related]
25. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells.
Knobel PA; Kotov IN; Felley-Bosco E; Stahel RA; Marti TM
Neoplasia; 2011 Oct; 13(10):961-70. PubMed ID: 22028621
[TBL] [Abstract][Full Text] [Related]
27. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
29. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
30. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
31. The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease.
Hays E; Nettleton E; Carter C; Morales M; Vo L; Passo M; Vélez-Cruz R
Cell Cycle; 2020 Nov; 19(22):3096-3114. PubMed ID: 33044911
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
33. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.
Guo Y; Tian P; Yang C; Liang Z; Li M; Sims M; Lu L; Zhang Z; Li H; Pfeffer LM; Yue J
Pharm Res; 2015 Mar; 32(3):769-78. PubMed ID: 25823356
[TBL] [Abstract][Full Text] [Related]
34. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
35. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
[TBL] [Abstract][Full Text] [Related]
36. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
37. Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.
Kramer D; Stark N; Schulz-Heddergott R; Erytch N; Edmunds S; Roßmann L; Bastians H; Concin N; Moll UM; Dobbelstein M
Cell Death Differ; 2017 Feb; 24(2):300-316. PubMed ID: 27834954
[TBL] [Abstract][Full Text] [Related]
38. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.
Nakada S; Yonamine RM; Matsuo K
Cancer Res; 2012 Oct; 72(19):4974-83. PubMed ID: 22865450
[TBL] [Abstract][Full Text] [Related]
39. MTA1 promotes cell proliferation via DNA damage repair in epithelial ovarian cancer.
Yang QY; Li JH; Wang QY; Wu Y; Qin JL; Cheng JJ; Qiu J
Genet Mol Res; 2014 Dec; 13(4):10269-78. PubMed ID: 25501238
[TBL] [Abstract][Full Text] [Related]
40. [Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells].
Yang Z; Sun C; Liu Y; Gong C; Chen G; Weng D
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):805-10. PubMed ID: 25620475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]